Par Drugs & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Q: What is the intrinsic value of Par Drugs & Chemicals Ltd?

Par Drugs & Chemicals Ltd's intrinsic value (as of 25 December 2025) is 130.55 which is 22.01% higher than the current market price of 107.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 132 Cr. market cap, FY2025-2026 high/low of 220/81.0, reserves of ₹94.13 Cr, and liabilities of 127.52 Cr.

Share Price and Basic Stock Data

Last Updated: December 24, 2025, 5:38 pm

Market Cap	132 Cr.
Current Price	107
High / Low	220/81.0
Stock P/E	13.6
Book Value	86.5
Dividend Yield	0.00 %
ROCE	18.4 %
ROE	13.6 %
Face Value	10.0
PEG Ratio	13.33

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Par Drugs & Chemicals Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	135 Cr.	107	231/84.3	29.8	49.6	0.00 %	12.9 %	9.69 %	10.0
MPS Pharmaa Ltd	3.54 Cr.	1.85	4.29/1.76		0.33	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	4,770 Cr.	438	479/192	98.8	24.3	0.15 %	27.3 %	21.7 %	1.00
Gujarat Terce Laboratories Ltd	34.9 Cr.	47.0	88.6/37.2		10.6	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	48.7 Cr.	33.3	35.0/17.0	116	6.93	0.00 %	13.5 %	11.0 %	10.0
Industry Average	20,181.97 Cr	1,153.40		53.07	202.18	0.35%	16.29%	15.20%	6.10

All Competitor Stocks of Par Drugs & Chemicals Ltd

Quarterly Result

Metric	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	23.51	24.82	22.93	24.49	22.93	25.89	24.00	22.82	22.61	34.66	21.38	22.33	26.05
Expenses	19.81	18.92	19.70	19.10	18.79	18.53	18.77	16.72	18.37	23.25	19.95	19.90	22.49
Operating Profit	3.70	5.90	3.23	5.39	4.14	7.36	5.23	6.10	4.24	11.41	1.43	2.43	3.56
OPM %	15.74%	23.77%	14.09%	22.01%	18.05%	28.43%	21.79%	26.73%	18.75%	32.92%	6.69%	10.88%	13.67%
Other Income	0.15	0.02	0.04	0.03	0.01	0.05	0.23	-0.05	0.07	1.02	0.27	0.79	1.84
Interest	0.05	0.03	0.03	0.03	0.02	0.03	0.02	0.05	0.02	0.03	0.01	0.02	0.02
Depreciation	0.73	0.91	0.74	0.85	0.83	0.85	0.87	0.89	0.90	0.91	0.91	0.92	0.90
Profit before tax	3.07	4.98	2.50	4.54	3.30	6.53	4.57	5.11	3.39	11.49	0.78	2.28	4.48
Tax %	25.08%	25.10%	25.20%	24.01%	25.15%	25.27%	25.16%	27.20%	25.07%	25.15%	24.36%	27.63%	25.67%
Net Profit	2.29	3.73	1.87	3.45	2.47	4.89	3.42	3.72	2.53	8.60	0.58	1.65	3.33
EPS in Rs	1.86	3.03	1.52	2.80	2.01	3.97	2.78	3.02	2.06	6.99	0.47	1.34	2.71

Last Updated: August 20, 2025, 5:45 am

Below is a detailed analysis of the quarterly data for Par Drugs & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

For Sales, as of Jun 2025, the value is 26.05 Cr.. The value appears strong and on an upward trend. It has increased from 22.33 Cr. (Mar 2025) to 26.05 Cr., marking an increase of 3.72 Cr..
For Expenses, as of Jun 2025, the value is 22.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.90 Cr. (Mar 2025) to 22.49 Cr., marking an increase of 2.59 Cr..
For Operating Profit, as of Jun 2025, the value is 3.56 Cr.. The value appears strong and on an upward trend. It has increased from 2.43 Cr. (Mar 2025) to 3.56 Cr., marking an increase of 1.13 Cr..
For OPM %, as of Jun 2025, the value is 13.67%. The value appears strong and on an upward trend. It has increased from 10.88% (Mar 2025) to 13.67%, marking an increase of 2.79%.
For Other Income, as of Jun 2025, the value is 1.84 Cr.. The value appears strong and on an upward trend. It has increased from 0.79 Cr. (Mar 2025) to 1.84 Cr., marking an increase of 1.05 Cr..
For Interest, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
For Depreciation, as of Jun 2025, the value is 0.90 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.92 Cr. (Mar 2025) to 0.90 Cr., marking a decrease of 0.02 Cr..
For Profit before tax, as of Jun 2025, the value is 4.48 Cr.. The value appears strong and on an upward trend. It has increased from 2.28 Cr. (Mar 2025) to 4.48 Cr., marking an increase of 2.20 Cr..
For Tax %, as of Jun 2025, the value is 25.67%. The value appears to be improving (decreasing) as expected. It has decreased from 27.63% (Mar 2025) to 25.67%, marking a decrease of 1.96%.
For Net Profit, as of Jun 2025, the value is 3.33 Cr.. The value appears strong and on an upward trend. It has increased from 1.65 Cr. (Mar 2025) to 3.33 Cr., marking an increase of 1.68 Cr..
For EPS in Rs, as of Jun 2025, the value is 2.71. The value appears strong and on an upward trend. It has increased from 1.34 (Mar 2025) to 2.71, marking an increase of 1.37.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 4:51 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	27.27	33.25	33.26	48.77	42.38	46.33	55.85	60.75	75.07	95.75	95.64	100.97	98.42
Expenses	20.01	25.88	26.07	40.31	34.40	38.13	46.41	44.74	58.82	77.55	72.82	81.47	84.94
Operating Profit	7.26	7.37	7.19	8.46	7.98	8.20	9.44	16.01	16.25	18.20	22.82	19.50	13.48
OPM %	26.62%	22.17%	21.62%	17.35%	18.83%	17.70%	16.90%	26.35%	21.65%	19.01%	23.86%	19.31%	13.70%
Other Income	0.03	0.04	0.04	0.04	0.04	0.09	0.10	2.18	0.18	0.24	0.24	2.15	3.38
Interest	3.91	3.86	3.57	2.50	2.33	1.96	0.79	0.64	0.45	0.13	0.11	0.08	0.10
Depreciation	2.17	2.33	2.65	2.82	3.14	3.04	2.76	2.82	3.28	3.23	3.44	3.65	3.67
Profit before tax	1.21	1.22	1.01	3.18	2.55	3.29	5.99	14.73	12.70	15.08	19.51	17.92	13.09
Tax %	39.67%	27.05%	58.42%	42.14%	41.57%	23.71%	20.53%	21.11%	27.48%	24.87%	25.73%	25.50%
Net Profit	0.72	0.89	0.42	1.85	1.50	2.51	4.76	11.61	9.21	11.33	14.50	13.36	9.69
EPS in Rs	1.33	1.65	0.78	3.43	2.78	2.79	3.87	9.44	7.49	9.21	11.78	10.86	7.88
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	32.30%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	23.61%	-52.81%	340.48%	-18.92%	67.33%	89.64%	143.91%	-20.67%	23.02%	27.98%	-7.86%
Change in YoY Net Profit Growth (%)	0.00%	-76.42%	393.29%	-359.40%	86.25%	22.31%	54.27%	-164.58%	43.69%	4.96%	-35.84%

Par Drugs & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	12%
5 Years:	13%
3 Years:	10%
TTM:	10%

Compounded Profit Growth
10 Years:	31%
5 Years:	23%
3 Years:	13%
TTM:	-3%

Stock Price CAGR
10 Years:	%
5 Years:	33%
3 Years:	-17%
1 Year:	-58%

Return on Equity
10 Years:	16%
5 Years:	17%
3 Years:	17%
Last Year:	14%

Last Updated: September 5, 2025, 12:05 pm

Balance Sheet

Last Updated: December 4, 2025, 1:46 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	2.70	2.70	2.70	2.70	2.70	4.48	6.15	6.15	12.30	12.30	12.30	12.30	12.30
Reserves	7.71	8.58	8.91	10.75	12.25	24.55	34.46	46.06	47.57	58.93	73.33	86.67	94.13
Borrowings	44.12	38.46	36.49	30.55	28.87	11.58	6.01	8.32	0.00	0.00	0.00	0.00	0.00
Other Liabilities	6.86	8.85	9.93	12.05	10.12	10.66	13.49	15.86	18.82	17.64	15.98	20.42	21.09
Total Liabilities	61.39	58.59	58.03	56.05	53.94	51.27	60.11	76.39	78.69	88.87	101.61	119.39	127.52
Fixed Assets	47.06	45.11	42.61	41.53	39.04	36.34	34.40	29.91	34.10	38.45	41.31	38.91	37.70
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.74	4.52	0.25	0.25	0.03	0.00	0.07
Investments	0.00	0.00	0.06	0.06	0.06	0.06	0.06	0.01	0.01	0.01	0.01	25.07	26.72
Other Assets	14.33	13.48	15.36	14.46	14.84	14.87	24.91	41.95	44.33	50.16	60.26	55.41	63.03
Total Assets	61.39	58.59	58.03	56.05	53.94	51.27	60.11	76.39	78.69	88.87	101.61	119.39	127.52

Below is a detailed analysis of the balance sheet data for Par Drugs & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 12.30 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.30 Cr..
For Reserves, as of Sep 2025, the value is 94.13 Cr.. The value appears strong and on an upward trend. It has increased from 86.67 Cr. (Mar 2025) to 94.13 Cr., marking an increase of 7.46 Cr..
For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 21.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.42 Cr. (Mar 2025) to 21.09 Cr., marking an increase of 0.67 Cr..
For Total Liabilities, as of Sep 2025, the value is 127.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 119.39 Cr. (Mar 2025) to 127.52 Cr., marking an increase of 8.13 Cr..
For Fixed Assets, as of Sep 2025, the value is 37.70 Cr.. The value appears to be declining and may need further review. It has decreased from 38.91 Cr. (Mar 2025) to 37.70 Cr., marking a decrease of 1.21 Cr..
For CWIP, as of Sep 2025, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.07 Cr., marking an increase of 0.07 Cr..
For Investments, as of Sep 2025, the value is 26.72 Cr.. The value appears strong and on an upward trend. It has increased from 25.07 Cr. (Mar 2025) to 26.72 Cr., marking an increase of 1.65 Cr..
For Other Assets, as of Sep 2025, the value is 63.03 Cr.. The value appears strong and on an upward trend. It has increased from 55.41 Cr. (Mar 2025) to 63.03 Cr., marking an increase of 7.62 Cr..
For Total Assets, as of Sep 2025, the value is 127.52 Cr.. The value appears strong and on an upward trend. It has increased from 119.39 Cr. (Mar 2025) to 127.52 Cr., marking an increase of 8.13 Cr..

Notably, the Reserves (94.13 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	5.30	8.94	6.53	9.17	4.32	2.10	7.69	12.09	7.62	13.38	20.25	16.16
Cash from Investing Activity +	-6.17	-0.34	-0.17	-1.70	-0.60	-0.25	-1.46	0.05	-3.02	-7.34	-5.84	-25.24
Cash from Financing Activity +	1.58	-9.31	-5.46	-8.38	-3.67	-1.88	1.11	1.65	-9.55	0.00	0.00	0.00
Net Cash Flow	0.71	-0.70	0.90	-0.91	0.05	-0.03	7.35	13.78	-4.96	6.04	14.41	-9.08

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-36.86	-31.09	-29.30	-22.09	-20.89	-3.38	3.43	7.69	16.25	18.20	22.82	19.50

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	104	83	81	61	75	67	81	75	90	65	52	60
Inventory Days	129	111	158	69	83	81	45	50	60	49	45	58
Days Payable	171	184	183	135	107	94	96	112	135	73	58	104
Cash Conversion Cycle	62	10	57	-5	51	55	30	13	14	40	40	15
Working Capital Days	102	61	66	-46	-26	13	39	24	61	50	40	39
ROCE %		10%	9%	12%	11%	12%	16%	25%	22%	23%	25%	18%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	74.21%	74.21%	74.21%	74.21%	74.21%	74.21%	74.21%	73.37%	73.37%	73.37%	73.37%	73.37%
FIIs	0.00%	0.00%	0.00%	0.00%	0.07%	0.07%	0.32%	0.09%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	25.79%	25.79%	25.79%	25.79%	25.73%	25.68%	25.47%	26.54%	26.63%	26.63%	26.63%	26.63%
No. of Shareholders	5,676	5,585	5,686	5,902	7,020	7,403	8,022	8,757	17,189	15,472	14,887	14,280

Shareholding Pattern Chart

No. of Shareholders

Par Drugs & Chemicals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	10.86	11.78	9.21	7.49	18.87
Diluted EPS (Rs.)	10.86	11.78	9.21	7.49	18.87
Cash EPS (Rs.)	13.82	14.58	11.84	10.15	23.45
Book Value[Excl.RevalReserv]/Share (Rs.)	80.44	69.59	57.90	48.66	84.87
Book Value[Incl.RevalReserv]/Share (Rs.)	80.44	69.59	57.90	48.66	84.87
Dividend / Share (Rs.)	0.00	0.00	0.00	1.25	0.00
Revenue From Operations / Share (Rs.)	82.06	77.73	77.81	61.01	98.75
PBDIT / Share (Rs.)	17.60	18.74	14.99	13.36	26.34
PBIT / Share (Rs.)	14.63	15.95	12.36	10.69	21.75
PBT / Share (Rs.)	14.57	15.86	12.25	10.32	20.71
Net Profit / Share (Rs.)	10.86	11.79	9.21	7.49	18.87
PBDIT Margin (%)	21.44	24.11	19.26	21.89	26.66
PBIT Margin (%)	17.83	20.51	15.88	17.52	22.02
PBT Margin (%)	17.75	20.40	15.74	16.92	20.97
Net Profit Margin (%)	13.22	15.16	11.83	12.27	19.11
Return on Networth / Equity (%)	13.49	16.93	15.91	15.38	22.23
Return on Capital Employeed (%)	17.51	22.00	20.31	20.61	22.15
Return On Assets (%)	11.18	14.27	12.75	11.70	15.20
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.08
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.14
Asset Turnover Ratio (%)	0.91	1.00	1.14	0.96	0.89
Current Ratio (X)	3.31	4.79	3.53	2.93	2.58
Quick Ratio (X)	2.94	4.46	3.15	2.61	2.39
Inventory Turnover Ratio (X)	19.64	6.97	8.13	7.68	7.47
Dividend Payout Ratio (NP) (%)	0.00	0.00	0.00	16.69	0.00
Dividend Payout Ratio (CP) (%)	0.00	0.00	0.00	12.31	0.00
Earning Retention Ratio (%)	0.00	0.00	0.00	83.31	0.00
Cash Earning Retention Ratio (%)	0.00	0.00	0.00	87.69	0.00
Interest Coverage Ratio (X)	263.72	215.31	138.48	36.19	25.22
Interest Coverage Ratio (Post Tax) (X)	163.70	136.40	86.09	21.28	15.99
Enterprise Value (Cr.)	76.93	228.45	150.02	180.36	62.64
EV / Net Operating Revenue (X)	0.76	2.39	1.57	2.40	1.03
EV / EBITDA (X)	3.55	9.91	8.13	10.97	3.87
MarketCap / Net Operating Revenue (X)	1.03	2.77	1.80	2.62	1.25
Retention Ratios (%)	0.00	0.00	0.00	83.30	0.00
Price / BV (X)	1.06	3.10	2.42	3.28	1.46
Price / Net Operating Revenue (X)	1.03	2.77	1.80	2.62	1.25
EarningsYield	0.12	0.05	0.06	0.04	0.15

After reviewing the key financial ratios for Par Drugs & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
For Diluted EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
For Cash EPS (Rs.), as of Mar 25, the value is 13.82. This value is within the healthy range. It has decreased from 14.58 (Mar 24) to 13.82, marking a decrease of 0.76.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.06. It has increased from 77.73 (Mar 24) to 82.06, marking an increase of 4.33.
For PBDIT / Share (Rs.), as of Mar 25, the value is 17.60. This value is within the healthy range. It has decreased from 18.74 (Mar 24) to 17.60, marking a decrease of 1.14.
For PBIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.95 (Mar 24) to 14.63, marking a decrease of 1.32.
For PBT / Share (Rs.), as of Mar 25, the value is 14.57. This value is within the healthy range. It has decreased from 15.86 (Mar 24) to 14.57, marking a decrease of 1.29.
For Net Profit / Share (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.79 (Mar 24) to 10.86, marking a decrease of 0.93.
For PBDIT Margin (%), as of Mar 25, the value is 21.44. This value is within the healthy range. It has decreased from 24.11 (Mar 24) to 21.44, marking a decrease of 2.67.
For PBIT Margin (%), as of Mar 25, the value is 17.83. This value is within the healthy range. It has decreased from 20.51 (Mar 24) to 17.83, marking a decrease of 2.68.
For PBT Margin (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has decreased from 20.40 (Mar 24) to 17.75, marking a decrease of 2.65.
For Net Profit Margin (%), as of Mar 25, the value is 13.22. This value exceeds the healthy maximum of 10. It has decreased from 15.16 (Mar 24) to 13.22, marking a decrease of 1.94.
For Return on Networth / Equity (%), as of Mar 25, the value is 13.49. This value is below the healthy minimum of 15. It has decreased from 16.93 (Mar 24) to 13.49, marking a decrease of 3.44.
For Return on Capital Employeed (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 22.00 (Mar 24) to 17.51, marking a decrease of 4.49.
For Return On Assets (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 14.27 (Mar 24) to 11.18, marking a decrease of 3.09.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.91. It has decreased from 1.00 (Mar 24) to 0.91, marking a decrease of 0.09.
For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 3.31, marking a decrease of 1.48.
For Quick Ratio (X), as of Mar 25, the value is 2.94. This value exceeds the healthy maximum of 2. It has decreased from 4.46 (Mar 24) to 2.94, marking a decrease of 1.52.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 19.64. This value exceeds the healthy maximum of 8. It has increased from 6.97 (Mar 24) to 19.64, marking an increase of 12.67.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Interest Coverage Ratio (X), as of Mar 25, the value is 263.72. This value is within the healthy range. It has increased from 215.31 (Mar 24) to 263.72, marking an increase of 48.41.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.70. This value is within the healthy range. It has increased from 136.40 (Mar 24) to 163.70, marking an increase of 27.30.
For Enterprise Value (Cr.), as of Mar 25, the value is 76.93. It has decreased from 228.45 (Mar 24) to 76.93, marking a decrease of 151.52.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 2.39 (Mar 24) to 0.76, marking a decrease of 1.63.
For EV / EBITDA (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 5. It has decreased from 9.91 (Mar 24) to 3.55, marking a decrease of 6.36.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 1.06, marking a decrease of 2.04.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
For EarningsYield, as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 0.12, marking an increase of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Par Drugs & Chemicals Ltd as of December 25, 2025 is: ₹130.55

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 25, 2025, Par Drugs & Chemicals Ltd is Undervalued by 22.01% compared to the current share price ₹107.00

Intrinsic Value of Par Drugs & Chemicals Ltd as of December 25, 2025 is: ₹131.88

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 25, 2025, Par Drugs & Chemicals Ltd is Undervalued by 23.25% compared to the current share price ₹107.00

Last 5 Year EPS CAGR: 1.02%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 15.25%, which is a positive sign. The company has higher reserves (39.53 cr) compared to borrowings (15.72 cr), indicating strong financial stability. The company has shown consistent growth in sales (62.59 cr) and profit (8.58 cr) over the years.	The stock has a high average Working Capital Days of 35.25, which may not be favorable. The stock has a high average Cash Conversion Cycle of 31.83, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Par Drugs & Chemicals Ltd:
1. Net Profit Margin: 13.22%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 17.51% (Industry Average ROCE: 16.29%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 13.49% (Industry Average ROE: 15.2%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 163.7
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.94
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 13.6 (Industry average Stock P/E: 53.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Par Drugs & Chemicals Ltd. is a Public Limited Listed company incorporated on 26/02/1999 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24117GJ1999PLC035512 and registration number is 035512. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 100.97 Cr. and Equity Capital is Rs. 12.30 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	815, Nilamber Triumph, Vadodra Gujarat 390007	Contact not found

Management
Name	Position Held
Mr. Falgun Vallabhbhai Savani	Chairman & Managing Director
Mr. Jignesh Vallabhbhai Savani	Executive Director & CEO
Mr. Pravin Manjibhai Bhayani	Independent Director
Mrs. Kajal Chintanbhai Vaghani	Independent Director
Mrs. Krishna Mitulbhai Shah	Independent Director
Mrs. Bintal Bhaveshkumar Shah	Independent Director

FAQ

What is the intrinsic value of Par Drugs & Chemicals Ltd?

Par Drugs & Chemicals Ltd's intrinsic value (as of 24 December 2025) is 130.55 which is 22.01% higher the current market price of 107.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 132 Cr. market cap, FY2025-2026 high/low of 220/81.0, reserves of ₹94.13 Cr, and liabilities of 127.52 Cr.

What is the Market Cap of Par Drugs & Chemicals Ltd?

The Market Cap of Par Drugs & Chemicals Ltd is 132 Cr..

What is the current Stock Price of Par Drugs & Chemicals Ltd as on 24 December 2025?

The current stock price of Par Drugs & Chemicals Ltd as on 24 December 2025 is 107.

What is the High / Low of Par Drugs & Chemicals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Par Drugs & Chemicals Ltd stocks is 220/81.0.

What is the Stock P/E of Par Drugs & Chemicals Ltd?

The Stock P/E of Par Drugs & Chemicals Ltd is 13.6.

What is the Book Value of Par Drugs & Chemicals Ltd?

The Book Value of Par Drugs & Chemicals Ltd is 86.5.

What is the Dividend Yield of Par Drugs & Chemicals Ltd?

The Dividend Yield of Par Drugs & Chemicals Ltd is 0.00 %.

What is the ROCE of Par Drugs & Chemicals Ltd?

The ROCE of Par Drugs & Chemicals Ltd is 18.4 %.

What is the ROE of Par Drugs & Chemicals Ltd?

The ROE of Par Drugs & Chemicals Ltd is 13.6 %.

What is the Face Value of Par Drugs & Chemicals Ltd?

The Face Value of Par Drugs & Chemicals Ltd is 10.0.